

1 **Role of polyphenols and polyphenol-rich foods in the modulation of PON1 activity and**
2 **expression**

3 **Daniela Martini¹, Cristian Del Bo^{2,*}, Marisa Porrini², Salvatore Ciappellano² and Patrizia**
4 **Riso²**

5 ¹LS9 Interlab Group, The Laboratory of Phytochemicals in Physiology, Department of Food
6 Science, University of Parma, Medical School, Building C, Via Volturno 39, 43125 Parma, Italy

7 ²Università degli Studi di Milano, Department of Food, Environmental and Nutritional Sciences,
8 Division of Human Nutrition, Via G. Celoria 2, 20133 Milano, Italy

9
10
11 ***Corresponding author:** Dr. Cristian Del Bo', Università degli Studi di Milano, Department of
12 Food, Environmental and Nutritional Sciences, Division of Human Nutrition, Via G. Celoria 2,
13 20133 Milano, Italy. Tel +39 02 503 16727; Fax +39 02 503 16721; email:
14 cristian.delbo@unimi.it

15

16 **RUNNING TITLE:** Polyphenols in the modulation of paraxonase-1

17

18 **KEYWORDS**

19 Polyphenols; Polyphenol-rich foods; Paraoxonase-1; *in vitro* studies; *in vivo* studies

20

21

22

23

24

25

26

27 **ABSTRACT**

28 Paraoxonase 1 (PON1) is a HDL-associated enzyme involved in the protection of LDL and HDL-
29 lipoproteins against lipid peroxidation. Several studies documented the capacity of polyphenols
30 to stimulate PON1 transcription activation.

31 The objective of the present review is to provide the main evidence about the role and the
32 potential mechanism of action of polyphenols and polyphenol-rich foods in the modulation of
33 PON1 gene expression and activity.

34 A total of 76 *in vitro* and *in vivo* studies were included in the review. Overall, while evidence
35 obtained *in vitro* are limited to quercetin and resveratrol, those deriving from animal models
36 seem more convincing for a wide range of polyphenols but only at pharmacological doses.

37 Evidence from human studies are promising but deserve more substantiation about the role of
38 polyphenol-rich foods in the regulation of PON1 activity and expression.

39 Research focused on the understanding of the structure-activity relationship of polyphenols
40 with PON1 and on the mechanisms at the base of PON1-modulation is warranted. Well-
41 designed human intervention studies are encourage to corroborate the findings of polyphenols
42 also at physiological doses.

43

44

45 **1.INTRODUCTION**

46 Paraoxonases (PON) are a family of three enzymes named PON1, PON2 and PON3. PON1 and
47 PON3 are predominantly synthesized in the liver and secreted into the plasma where they are
48 associated with HDL. PON2 is not generally present in plasma but widely distributed also in
49 cells and tissues such as liver and kidneys. Both PON2 and PON3 have antioxidant properties
50 but lack of paraoxonase or arylesterase activities compared to PON1. Although all the three
51 enzymes have shown anti-atherogenic activity, PON1 is considered the major protective factor
52 against LDL and HDL oxidation [1]. Studies investigating the role of PON1 in cardiovascular
53 disease have provided evidence that PON1 status is a better predictor of disease than PON2 and
54 PON3. The mechanism by which PON1 protect LDL from oxidation seems to be related to its
55 capacity to hydrolyze oxidized fatty acids derived from phospholipids, cholesterylester and
56 triglycerides hydroperoxides that are potentially atherogenic compounds [2]. In this regard, data
57 from several animal models of atherosclerosis demonstrated the ability of PON1 to retard and
58 reverse atherosclerosis through a reduction of oxidized-LDL, a reduction of macrophages
59 oxidative stress and foam cell formation, an increase in reverse cholesterol transport and an
60 improvement of arterial function. In addition, PON1 is involved in the detoxification of
61 homocysteine (Hcy)-thiolactone, a reactive metabolite that, through a process of N-
62 homocysteinylolation, affects the structure and function of proteins and lipoproteins including
63 HDL [3].

64 Several studies support the hypothesis that a low paraoxonase and lactonase activity of
65 PON1 has been associated with an increased oxidative stress and vulnerability to plaque
66 formation, atherosclerosis and cardiovascular diseases [1,4-9]. Moreover, alterations in
67 circulating PON1 levels have been found in a variety of diseases including diabetes mellitus,
68 hepatic and renal diseases, psoriasis and rheumatoid arthritis [10]. **It is well know that PON1**
69 **activity can be influenced by several factors such as lifestyle and diet.**

70 Very recently, Lou-Bonafante and colleagues critically revised the role of Mediterranean
71 diet, and its components, in the modulation of PON1 activity [11]. The authors suggested that
72 the Mediterranean diet, through the intake of nuts, fruit and vegetable may affect PON1 activity
73 by protecting the enzyme from oxidative stress-induced inactivation and/or by improving its
74 activity.

75 Regarding the effects of dietary constituents, several *in vivo* studies showed an increase in
76 PON1 activity/expression following vitamin C [12-13], vitamin E [14-16], folate [13],
77 carotenoids [17], mono- and poly- unsaturated fatty acids [18-22], selenium [21,22], and
78 polyphenols supplementation [23-25]. Polyphenols are a heterogeneous family of bioactive
79 compounds widely distributed in the plant kingdom. Chemically, they are characterized by the
80 common presence of at least one aromatic ring in their structure, linked with other phenolic-,
81 hydroxyl-, carbon- or other chemical groups [26]. Polyphenols can be classified into *flavonoids*
82 (i.e. flavonols, flavanones, flavones, isoflavones, anthocyanidins, and flavan-3-ols) and
83 *nonflavonoids* (i.e. condensed and hydrolysable tannins, stilbenes, phenolic acids,
84 hydroxibenzoic and hydroxycinnamic acids and lignans) depending of their chemical structure
85 [26,27]. They can be in the form of oligomers and polymers, or esterified with other chemical
86 compounds (mainly sugars or organic acids), while rarely are present as aglycones (without
87 sugar). Minor *nonflavonoids* include also derivatives of colonic microbiota metabolites such as
88 phenylvaleric, phenyl-lactic, phenylpropionic, phenylmandelic and phenylhydracrylic acid [28].

89 In the last years, several studies focused on the bioactivity of polyphenols and polyphenol-rich
90 foods. Most of the studies have been performed *in vitro* and in animal models, while limited are
91 those in humans. In particular, observational and intervention studies documented an effect of
92 polyphenols in the prevention/modulation of metabolic syndrome [28], endothelial dysfunction
93 [29], hypertension [30-32] and cardiovascular and coronary diseases [33,,34]. The effects seem
94 related to the antioxidant and anti-inflammatory activity [35,36], to vascular function
95 modulation [33,37] and to lipid/cholesterol regulation [38]. In addition, it has been hypothesized

96 that polyphenols effects may be mediated also by the regulation of PON1 activity and gene
97 expression. In the present review, we attempt to summarize the main evidence on the potential
98 effects of polyphenols and polyphenol-rich foods on PON1 expression and activity also
99 considering, when available, the contribution of genetic factors and the mechanisms of action.
100 The review will focus on both *in vitro* and *in vivo* studies.

101 **2.OVERVIEW OF *IN VITRO* AND *IN VIVO* STUDIES ON POLYPHENOLS AS** 102 **MODULATORS OF PON1 EXPRESSION AND ACTIVITY**

103 A **systematic** search for literature focused on the effect of polyphenols and polyphenol-rich
104 foods in the modulation of PON1 was carried out. **The search of the studies was performed**
105 **based on the preferred Reporting Items for Systematic Review and Meta-Analysis (PRISMA)**
106 **flow diagram (Figure 1).** PUBMED, ScienceDirect and Scopus databases were searched to
107 identify pertinent articles. **The systematic computerized literature search was performed from**
108 **January 2000 up to November 2016.** The exploration used the combination of the following
109 terms: ‘polyphenols’, ‘**polyphenol-rich foods**’, ‘flavonoids’, ‘anthocyanins’ and ‘paraoxonase
110 1’. Reference lists of the obtained papers were also searched for additional articles. **The**
111 **selection of the *in vitro* and *in vivo* studies was performed according to the following inclusion**
112 **and exclusion criteria. *Inclusion criteria:* 1- be performed in cells and/or in animal models**
113 **and/or in humans; 2-be a study evaluating PON-1 activity and/or expression; 3-be a study**
114 **evaluating polyphenols and/or polyphenol-rich foods. *Exclusion criteria:* a) evaluating foods not**
115 **having polyphenols as major bioactive compounds; b) performed *in vitro* but not using cells; c)**
116 **written not in English; d) performed without a statistical analysis. A total of 406 records were**
117 **screened and 323 out of them were excluded based on title or abstract or because duplicate**
118 **papers. Eighty-three full-text articles were obtained from the databases and from the reference**
119 **lists of the obtained papers. Based on the full-text, inclusion and exclusion criteria, 7 articles**
120 **were excluded while 76 papers were analyzed.** Five of them combined two or three experimental

121 models [39-43] for a total of 81 studies. Among them, 11 were *in vitro* studies, 44 were
122 performed on animal models and 26 were intervention studies in humans. The studies included
123 in the review are described in **Tables 1-3** (*provided as supplemental material*) and the following
124 details were included: polyphenol/s or polyphenol rich-food (composition was reported when
125 available) tested, cell model, animal model or subjects selected and their characteristics, study
126 design, type of intervention and main findings.

127

128 2.1 *In vitro* studies

129 Eleven *in vitro* studies evaluated the role of polyphenols and polyphenol-rich extracts on PON1
130 expression and activity (*see* Supplementary **Table 1** under “Supplemental data” in the online
131 issue) [39,42-51].

132 The main polyphenols considered were resveratrol [47-51], used in two studies also as positive
133 control [42,43], and quercetin [39,43,45]. The human hepatoma cell line Huh7 was the main cell
134 line tested, being utilized in 9 out of the 11 *in vitro* studies considered [39,42-45,49,50]. The
135 duration of treatments generally ranged from 24 to 48 h, while the doses of resveratrol ranged
136 from 2 to 25 μM with the exception of one study that used also concentrations of 200 μM [48].
137 Gouédard *et al.*[44] and Guyot *et al.*[50] reported an increased PON1 gene expression in human
138 hepatocyte primary cultures and in HuH7 hepatoma cell line following 48 h supplementation
139 with 10 μM of resveratrol. Similar results were also observed by Gupta and colleagues
140 following incubation of HepG2 cells for 48 h with 15 μM of resveratrol [51]. Curtin *et al.*[50]
141 found the optimal induction of intracellular and extracellular PON1 activity within 2–20 μM of
142 resveratrol while no effect was observed at doses higher than 20 μM , which in turn resulted
143 cytotoxic leading to a decrease of cell metabolic activity.

144 Three studies found a dose-dependent increase of PON1 activity [42,45,46]. Schrader and
145 colleagues documented that Huh7 liver hepatoma cells supplemented with curcumin (1-20 μM
146 for 48 h) increased PON1 activation in a dose-dependent manner for concentrations higher than

147 10 μM [42]. Khateet *et al.*[46] reported that supplementation with pomegranate juice
148 polyphenols such as punicalagin and gallic acid (from 17.5 to 70 μg gallic acid equivalent/mL
149 for 24 h) increased HuH7 hepatocyte-secreted PON1 arylesterase activity and the effect was
150 dose-dependent. Garige and coworkers showed a progressive up-regulation of PON1 expression
151 and activity following increasing quercetin supplementation (from 0 to 20 μM for 48 h) in
152 HuH7 cell line [45].

153 On the whole, studies documented a different effect of polyphenols in the modulation of
154 PON1 activity and expression dependent on the compound tested. For example, Gouédard *et al.*
155 [45] reported that supplementation of HuH7 cells for 48 h with flavone, catechin and quercetin
156 (10 μM) and naringenin (50 μM) resulted in a significant increase of PON-1 activity even if the
157 maximum induction was observed only with quercetin. Schader *et al.*[39] studied the effect of
158 different flavonoids (concentration range 1–25 μM for 48 hrs) on induction of PON1 in stably
159 transfected Huh7 liver cells. The authors documented that genistein was the most potent
160 flavonoid with PON1-inducing activity, followed by daidzein, luteolin, isorhamnetin and
161 quercetin. Other flavonoids such as naringenin, cyanidin, malvidin and catechin showed only
162 little or no PON1-inducing activity. Quercetin and resveratrol proved to increase both PON1
163 mRNA expression and PON1 activity when compared to the related control groups (untreated
164 cells). However, a comparison of the findings from the different studies appear complicated due
165 to the variability in terms of type and dose of compounds tested.

166

167 2.2 Animal studies

168 The effect of polyphenols and polyphenol-rich foods on animal models has been evaluated in 44
169 studies (*see* Supplementary **Table 2** under “Supplemental data” in the online issue)
170 [25,39,40,42,43,52-90]. Most of them were performed on mice or rats, while two studies on
171 hamsters [62,74]. The main polyphenols tested were quercetin [43,52,54,58,63,68,71,87] and
172 catechin [54,58,71,87], whereas pomegranate juice was the most polyphenol-rich food used

173 [40,53,69,72] followed by vegetable oils [62,77,81]. Several studies were also performed using
174 grapevine derived products in the form of extracts or concentrate [25,67,79], red wine [54] or
175 polyphenols [64]. Numerous studies did not provide information regarding the polyphenols
176 concentration of food [25,53,56,57,69,70,78,85,87]. Other studies provided only an estimation
177 of the polyphenol content evaluated through indirect techniques, for example measuring the total
178 phenolic content by the Folin-Ciocalteu method. This lack of information makes comparison
179 among studies, even those using the same food, particularly complex. All the studies were
180 placebo-controlled. A large variability regarding the duration of the interventions (ranging from
181 2 to 20 weeks), as well as the dose of the tested compounds was observed. In spite of this, 39
182 out of 44 studies found a significant effect of supplementation with polyphenols on PON1
183 expression and/or activity. No effect was found in 5 studies [39,40,56,82]. The lack of effect
184 could be, at least in part, related to the relatively short duration of the intervention in several
185 studies (2-3 weeks) [39,42,56,88] compared to others (12-20 weeks)
186 [40,53,60,64,65,70,74,75,78,80]. For example, El-Beshbishy *et al.* [56] documented that the
187 intake of a polyphenol-rich food (500 mg kg⁻¹ day) for 2 weeks did not increase serum PON1
188 activity in rats, but showed to protect LDL from oxidation hypothesizing that this effect was not
189 mediated by PON1 but a direct effect of polyphenols on LDL itself. Schrader *et al.*[39] failed to
190 observe a modulation on plasma PON1 activity in rats fed with genistein for 3 weeks, in spite
191 the same authors found genistein as the most potent inducer of PON1-transactivation at
192 concentrations higher than 5 µM in the cell model. Other than duration of the study, the lack of
193 effects on PON1 mRNA induction, protein and activity levels in the *in vivo* study may be
194 attributed to the concentrations of genistein that were much higher than those found in plasma
195 and liver of rats.

196 Some investigations revealed high variability in PON1 gene expression and activity
197 when using the same compound or food. For instance, 3 studies documented an increase in
198 PON1 expression following quercetin administration, while no effect was observed after

199 catechin [54,71,88] which was suggested to be a poor inducer of PON1 mRNA and PON1
200 transactivation. On the contrary, Hamelet *et al.*[58] found catechin, but not quercetin, able to
201 counteract homocysteine-induced impairment of PON1 gene expression and activity in liver of
202 hyperhomocysteinemic mice. These conflicting results may be at least partially explained by the
203 different animal model used or different absorption and metabolism of polyphenols.

204 Regarding the studies investigating the effect of pomegranate juice intake, a significant
205 increase in PON1 activity was found by Kaplan *et al.*[53] and Rosenblat *et al.*[69] who showed
206 a significant increase in serum PON activity in mice supplemented with pomegranate for 1 and 2
207 months, respectively. Similarly, Betanzos-Cabrera *et al.*[72] documented a significant increase
208 in liver PON1 activity after 4 months of supplementation with pomegranate juice (0.35 mmol/L)
209 used in combination with a high fat diet compared to the high fat diet alone, but not compared to
210 the control group. Conversely, Aviram *et al.*[40] showed no effect on PON1 activity in mice
211 following 14 weeks of supplementation with 6.25 or 12.5 mL pomegranate juice/day
212 (corresponding to 0.175 and 0.350 mmol of total polyphenols, respectively). This variability
213 among studies suggests that many variables (e.g. dose and duration of the studies, animal
214 model) may affect findings from different studies.

215

216 2.3 Human studies

217 The effect of polyphenols and polyphenol-rich foods on PON1 gene expression and activity has
218 been investigated in 26 human intervention studies (*see* Supplementary **Table 3** under
219 “Supplemental data” in the online issue) [40,41,43,91-113]. Differently from what observed in
220 *in vitro* and animal studies, the evidence of a modulation of PON1 expression and activity
221 through polyphenols is promising but needs more substantiation. In fact, half of the studies
222 reported an increase in PON1 expression and/or activity, while the other half showed no effect
223 or even a reduction following polyphenol/polyphenol-rich food supplementation. These
224 conflicting findings can be attributed to large differences among studies such as experimental

225 design, duration of the intervention, type of food and amount used, and last but not least, the
226 study population selected. In this regard, 13 out of 26 studies were performed on healthy
227 volunteers [40,41,43,91,94,96,100,101,104,107,108,110,112], whereas the remaining 13
228 investigations involved subjects with asymptomatic severe carotid artery stenosis [93], diabetes
229 [95,99,103,105,106], peripheral arterial disease [97], cardiovascular risk [92,102,110,111],
230 hemodialysis [113] and end-stage renal disease [98].

231 Regarding the study design, 14 studies did not include a control group evaluating the effects at
232 baseline and post-intervention with polyphenols or polyphenol-rich foods [41,42,92,94,95,98-
233 100,103,105,107,108,110,112]. A cross-over design was adopted in 5 studies
234 [96,97,101,104,111], while 7 studies used a parallel design [43,91,93,102,106,109,113].

235 Twenty-three out of 26 trials investigated the effect of polyphenol-rich foods in the medium-
236 long term, with a duration generally ranging from 2 to 24 weeks [40,43,91-97,99-103,105-113]
237 except for one study that was a 3-year long term intervention [93]. Three studies evaluated also
238 the effect of a single serving of decaffeinated green tea extracts, blackcurrant-based juice and 5
239 different beverages and wine on PON1 activity [41,104,108]. Compared to the long-term
240 intervention, the acute effect of polyphenol-rich foods failed to positively modulate the activity
241 of PON1. Only the administration of an orale dose of decaffeinated green tea extracts (455 mg
242 equivalent to 4 cups of green tea) showed to increase PON1 activity in a group of end-stage
243 renal disease patients.

244 Pomegranate and derived products were the most examined food
245 [40,41,93,95,101,103,105,112,113], followed by berries provided mainly in the form of juice
246 [41,104,106,108]. The amount of food varied depending on the type of product and bioactive
247 composition. For example, the amount of pomegranate and berry juice, and red wine ranged
248 from 50 to 250 mL/day while that of virgin and extravirgin olive oil was around 25 mL/day.

249 Eight studies did not provide information about the food matrix composition of polyphenols
250 [91,92,97,100,105-107,109,112], while 10 trials provided an estimation of the total polyphenols

251 content [40,41,94,99,101,103,104,108,111,113]. Regarding pomegranate, a significant
252 modulation of PON1 activity was observed both in healthy and unhealthy subjects at low doses
253 (50 mL per day). For example, Aviram *et al.*[40] showed that a 2-week consumption of
254 pomegranate juice (PJ; 50 mL/day) significantly increased serum PON1 activity in a group of
255 healthy subjects. The same authors reported an improvement of PON1 activity in a group of
256 patients with asymptomatic severe carotid artery stenosis following 1-3 year of PJ intervention
257 (50 mL/day) [93]. Rosenblat and coworkers found an increase in serum PON1 arylesterase
258 activity after 12 weeks of PJ in a group of diabetic subjects [95]. A 4 and 6-week intervention
259 with PJ (50 mL/day) and pomegrate extract contributed to PON1 stabilization, increased
260 association with HDL, and enhanced catalytic activities in a group of diabetic and overweight
261 individuals [99]. Moreover, Fuhrman and colleagues documented that a 4-week intake of PJ (50
262 mL/day) increased HDL-rePON1/free rePON1 ratio in diabetic subjects [103]. Only 2 studies
263 utilized PJ at higher doses [41,105]. Rosenblat *et al.*[41] showed that 250 mL/day of PJ per 1
264 week improved serum PON1 lactonase activity in healthy subjects, while no effect was observed
265 following a single dose of PJ. Finally, a 6-week intervention with PJ (200 mL/day) documented
266 an increase in paraoxonase and aryl esterase PON1 activity in a group of diabetic subjects [105].

267 Two studies examined the role of pomegranate extract on PON-1 activity [112,113].
268 Tracy *et al.*[112] reported that a 3-month supplementation with 1g per day of pomegranate
269 capsule extract increased serum PON-1 activity in a group of recurrent stone formers but not in
270 the non-stone former group. Wu and colleagues [113] showed that a daily oral supplementation
271 for 6 months of purified pomegranate extract (1g per day) improved serum PON-1 lactonase
272 activity (but not paraoxonase and arylesterase PON-1 activity) in a group of hemodialysis
273 patients.

274 The effect of berries, alone or in combination with other foods, on PON1 activity was
275 evaluated in 6 studies [40,91,97,104,106,108]. The results have shown high variability between
276 studies. For example, 1 week of intervention with blackcurrant juice (250 mL/day) increased

277 serum PON1 lactonase activity in healthy subjects [56]. In a double-blind randomized clinical
278 trial, the intake of 240 mL/day of cranberry juice for 12 weeks increased PON1 activity in type
279 2 diabetic male patients [106]. Conversely, Kardum *et al.*[108] reported no effect of a 12-week
280 intervention with polyphenol-rich chokeberry juice (100 mL/day) on PON1 activity in a group
281 of healthy subjects. Similar findings were also observed by Huebbe and colleagues, which
282 documented no effect on PON1 activity following a post-prandial consumption of 250 g of
283 blackcurrant-based juice [104].

284 Three studies specifically evaluated the effects of virgin and extravirgin olive oil, and
285 virgin argan oil [94,97,111]. Chercki *et al.* [94] showed that a 3-week intervention with 25
286 mL/day of virgin argan and extra virgin olive oil (providing about 3.3 mg/kg and 790 mg/kg of
287 total polyphenols, respectively) increased PON1 activity in a group of healthy subjects. Farràs
288 and coworkers [111] reported that a 3-week intervention with a functional virgin olive oil (25
289 mL/day providing about 500 ppm of total phenolic compounds) significantly improved PON1
290 activity in a group of hyperlipidemic individuals. On the contrary, Loued *et al.*[107]
291 documented that a 12-week intervention with extra virgin olive oil (25 mL/day) did not affect
292 serum PON1 activity in young and elderly healthy subjects.

293 A comparison of findings from animal and human studies testing the same food products
294 appears difficult since most of the animal studies used larger doses compared to those in human
295 trials. To give an example, the supplementation with 5-10 mL/day of pomegranate juice in mice
296 weighting ~200 g would correspond to 1.75-3.5 L/day when consumed by a subject of 70 kg.
297 Thus, an appropriate extrapolation of animal dose to human dose and viceversa through
298 normalization to the body surface area should be used.

299

300 **3. HYPOTHESIZED MECHANISMS OF PON1 REGULATION THROUGH POLYPHENOLS**

301 In **Figure 2** are reported the possible mechanisms of action of polyphenols in the regulation of
302 PON1 expression and activity. One of the most putative pathway of upregulation of PON1 could

303 be the activation of the AhR. The AhR is a ligand-activated transcription factor belonging to the
304 basic helix-loop-helix/per-aryl hydrocarbon receptor nuclear translocator protein-(ARNT)-
305 single-minded protein (Sim) family of proteins. It is classically activated by synthetic
306 xenobiotics such as dioxins, polycyclic aromatic hydrocarbons but also polyphenols (i.e.
307 resveratrol and quercetin). Upon ligand binding, AhR translocates to the nucleus and forms a
308 heterodimer with the ARNT. The AhR/ARNT heterodimer binds to xenobiotic responsive
309 elements (XREs) within the PON1 promoter (_126 and _106 region) and induces an
310 upregulation as documented in human breast cancer and hepatoma cell line following quercetin
311 supplementation [44,114].

312 Another plausible pathway could involve the transcription factor sterol regulatory
313 element-binding protein-2 (SREBP-2) via specificity protein 1 (Sp1). SREBPs are a new class
314 of membrane-bound transcription factors that modulate lipid homeostasis. SREBP-2 is the major
315 regulator of cholesterol biosynthetic pathway. Recent studies have reported that **quercetin** may
316 modulate PON1 gene via SREBP-2 [45,115]. In particular, it has been hypothesized that
317 quercetin can cause PON1 translocation through SREBP-2 from the endoplasmic reticulum to
318 the nucleus, where interacts with sterol responsive elements-like sequence on the PON1
319 promoter [45]. It has been reported that an interaction between Sp1 and protein kinase C (PKC)
320 could represent a potential mechanism of PON1 transcription in HuH7 liver cells [56]. This
321 process seems activated through a phosphorylation of PKC mediated by polyphenols (i.e.
322 resveratrol and epigallocatechin gallate) in HepG2 cells [116].

323 SREBP-2 is linked to p44/42 mitogen-activated protein kinase (MAPKs) signaling cascade.
324 MAPKs regulate the synthesis of chemokines, cytokines, adhesion molecules and
325 prostaglandins involved in inflammation. MAPKs seem to play an important role in the
326 regulation of PON1 activity and PON1 protein expression in Huh7 cells [117]. However, the
327 role of polyphenols on MAPK regulation has not been deeply investigated. For example,
328 epigallocatechin gallate has shown to inhibit interleukin-1beta-induced activation of MAPK in

329 human chondrocytes through the inhibition of c-Jun NH₂-terminal kinase (JNK) dependent
330 activity [118]. It is plausible that polyphenols may stimulate PON1 transcription through the
331 activation of JNK or acting as scavenger by inhibiting ROS production and oxidation. In this
332 regard, protocatechuic acid, the main metabolite of cyanidin-3-glucoside, was able to induce the
333 activation of JNK in macrophages which, in turn, determined the increase of nuclear receptor
334 Nrf2, leading to inhibition of the early ROS overproduction [119].

335 The intracellular signalling cascade of peroxisome proliferator-activated
336 receptors (PPARs) pathway plays a critical role in the regulation of diverse biologic processes
337 within the cardiovascular system, including PON activity. In this regard, recently pomegranate
338 juice polyphenols, gallic acid and ellagic acid were demonstrated to upregulate PON1
339 expression and PON1 release from hepatocytes through the activation of PKA and PPAR γ
340 signaling pathway [46].

341 Several studies have demonstrated that also inflammation can negatively affect PON1
342 activity [120]. The inflammatory process is orchestrated by nuclear factor kappa-B (NF- κ B), an
343 oxidative stress sensitive transcription factor, predominantly existing in the cytoplasm in an
344 inactive state bound to a member of the I κ B family of inhibitory proteins [121]. Phosphorylation
345 of I κ B by PKC or I κ B kinase (IKK) results in its degradation and dissociation from the NF- κ B
346 complex. Once NF- κ B is activated, it stimulates the expression of a number of genes including
347 those responsible for the production of cytokines and interleukins. The production of cytokines
348 and interleukins such as C reactive protein, interleukin-6, interleukin-1 and tumor necrosis
349 factor alpha have shown to reduce PON1 activity and PON1 mRNA levels in murine and human
350 hepatoma cell lines [120]. In particular, polyphenols have been recognized to block the
351 phosphorylation of I κ B by inhibiting the activation of NF- κ B and of the inflammatory cascade
352 as documented in *in vitro* and in animal models [122,123]. Inhibitors of NF- κ B translocation or
353 the transient over-expression of I κ B have shown to partially restore PON1 mRNA levels [120].

354 The specific chemical structure of polyphenols seems to have a role in the modulation of
355 PON1 activity and expression. The presence of hydroxyl groups on the flavonoid rings seems to
356 increase their affinity to re-PON1, while the glucuronidation and sulfatation processes, which
357 mask important hydroxyl groups of the flavonoid molecules decrease their PON1-inducing
358 activity. Flavones and flavonols (i.e. luteolin, quercetin, kaempferol and apigenin), that show
359 different numbers of hydroxyl groups on their rings, interact with higher affinity to re-PON1
360 than other flavonoids. These compounds present a double bond at their C ring, making it planar
361 due to coupling of the A and B rings' electrons, so the hydroxyl group at position 3 and the
362 oxygen at position 4 on the C ring are on the same plane [124].

363 However, the rePON1-flavonoid interaction, not only depends on the number and presence of
364 flavonoids hydroxyl groups, but also on the flavonoids substructure. In fact, although apigenin
365 and naringenin (flavone and flavanone, respectively) have the same number of hydroxyl groups
366 at the same positions, apigenin shows a higher affinity to PON1 than naringenin probably due to
367 a 2,4-substituted resorcinol moiety in the A ring [124].

368 Recently, Atrahymovic and colleagues showed that the isoflavan glabridin could link re-PON1,
369 despite the high hydrophobic subunit, protecting re-PON1 in a dose-dependent (1–100 μM)
370 manner [125]. The authors hypothesized that the mechanism governing the protective effect was
371 not related to the antioxidant action, but rather to a physical interaction with the enzyme. The
372 bind glabridin-re-PON1 affected the enzyme structure and significantly enhanced the ability of
373 the enzyme to remove Ox-LDL associated cholesteryl ester hydroperoxides.

374 The different chemical structure of polyphenols and the impact of PON1 polymorphisms in the
375 response make it difficult to elucidate the ability of these dietary compounds to modulate PON1
376 activity and gene expression and the specific mechanisms involved.

377

378 **4. CONCLUSIONS**

379 Several observational studies outlined the importance of PON1 in the prevention of
380 atherogenesis and preservation of HDL from oxidation. The mechanism by which PON1 can
381 preserve HDL from oxidation is not completely elucidated and more research should focus on
382 this aspect. In this context, the present review provides results supporting the role of
383 polyphenols in the modulation of PON1, even if much remains to ascertain. In fact, the studies
384 performed *in vitro* are few and most of the positive effects were observed only for quercetin and
385 resveratrol at doses not comparable to those achievable *in vivo*. The evidence deriving from
386 animal models seem to be more convincing; the majority of studies found a significant effect of
387 polyphenols and polyphenol-rich foods supplementation on both PON1 expression and PON1
388 activity, even if high doses have been generally used. Regarding human trials, it has been shown
389 a positive modulation of PON1 gene expression and activity following the consumption of some
390 polyphenol-rich foods, especially pomegranate juice at the dose of 50 mL/day. However, results
391 deserve further investigations because of some methodological issues. In fact, the population
392 characteristics were different among the studies and, in addition, in most of the trials the
393 experimental designs were not placebo-controlled. This latter represents a limitation, since it is
394 not clearly possible to attribute the effects observed specifically to the polyphenol-rich food
395 treatment.

396 Future studies should be performed to understand the mechanisms by which polyphenols can
397 modulate PON1 activity, and to verify whether the effects can be obtained at physiological
398 doses. This consideration highlights the importance of using reasonable doses of foods and
399 related bioactive compounds in intervention studies as suggested by the Food and Drug
400 Administration in clinical trials for therapeutics [126]. In addition, the adoption of rigorous and
401 well controlled human intervention studies is encouraged. Moreover, since polyphenols are
402 extensively metabolized in the human gut and liver, the contribution of their metabolic products
403 should be considered.

404

405 **5. ACKNOWLEDGMENTS**

406 Daniela Martini and Cristian Del Bo' performed the literature search, wrote the paper draft and
407 contributed to critical discussion of results. Marisa Porrini, Salvatore Ciappellano and Patrizia
408 Riso critically reviewed the paper literature and approved the final manuscript. The authors
409 declare no conflict of interest.

410

411 **6. REFERENCES**

- 412
413 [1] Litvinov D, Mahini H, Garelnabi M, Antioxidant and anti-inflammatory role of
414 paraoxonase 1: implication in arteriosclerosis diseases. *N Am J Med Sci.* 2012;4:523-32.
- 415 [2] Mackness B, Marsillach J, Elkeles RS, et al. Paraoxonase-1 is not associated with coronary
416 artery calcification in type 2 diabetes: results from the PREDICT study. *Dis. Markers.*
417 2012;33:101-112.
- 418 [3] Perła-Kaján J, Jakubowski H. Paraoxonase 1 and homocysteine metabolism. *Amino Acids*
419 2012;43:1405-17.
- 420 [4] Shekhanawar M, Shekhanawar SM, Krisnaswamy D, et al. The role of “paraoxonase-1
421 activity” as an antioxidant in coronary artery diseases. *J Clin Diagn. Res* 2013;7:1284-1287.
- 422 [5] Jayakumari N, Thejaseebai G. High prevalence of low serum paraoxonase-1 in subjects
423 with coronary artery disease. *J Clin Biochem Nutr.* 2009;45:278-284.
- 424 [6] Tavori H, Vaya J, Aviram M. Paraoxonase 1 attenuates human plaque atherogenicity:
425 relevance to the enzyme lactonase activity. *Adv Exp Med Biol.* 2010;660:99-111.
- 426 [7] Kowalska K, Socha E, Milnerowicz H. Review: The role of paraoxonase in cardiovascular
427 diseases. *Ann Clin Lab Sci* 2015;45:226-233.
- 428 [8] Cozzi L, Campolo J, Parolini M, et al. Paraoxonase 1 L55M, Q192R and paraoxonase 2
429 S311C alleles in atherothrombosis. *Mol Cell Biochem.* 2013;374:233-238.
- 430 [9] Furlong CE, Suzuki SM, Stevens RC, et al. Human PON1, a biomarker of risk of disease
431 and exposure. *Chem Biol Interact.* 2010;187:355-361.
- 432 [10] Mackness M, Mackness B. Human paraoxonase-1 (PON1): Gene structure and
433 expression, promiscuous activities and multiple physiological roles. *Gene* 2015;567:12-21
- 434 [11] Lou-Bonafonte JM, Gabás-Rivera C, Navarro MA, Osada J. PON1 and Mediterranean
435 Diet. *Nutrients.* 2015;7:4068-4092.

436 [12] Kunes JP, Cordero-Koning KS, Lee LH, Lynch SM. Vitamin C attenuates hypochlorite-
437 mediated loss of paraoxonase-1 activity from human plasma. *Nutr Res.* 2009;29:114-122.

438 [13] Gursu MF, Onderci M, Gulcu F, Sahin K. Effects of vitamin C and folic acid
439 supplementation on serum paraoxonase activity and metabolites induced by heat stress in vivo.
440 *Nutr Res.* 2004;24:157-164.

441 [14] Sarandol E, Tas S, Dirican M, Serdar Z. Oxidative stress and serum paraoxonase activity
442 in experimental hypothyroidism: effect of vitamin E supplementation. *Cell Biochem Funct.*
443 2005;23:1-8.

444 [15] Jeon SM, Park YB, Kwon OS, et al. Vitamin E supplementation alters HDL-cholesterol
445 concentration and paraoxonase activity in rabbits fed high-cholesterol diet: comparison with
446 probucol. *J Biochem Mol Toxicol.* 2005;19:336-346.

447 [16] Tsakaris S, Karika GA, Parthimos T, et al. Alpha-tocopherol supplementation prevents the
448 exercise-induced reduction of serum paraoxonase 1/arylesterase activities in healthy
449 individuals. *Eur J Clin Nutr.* 2009;63:215-221.

450 [17] Baralic I, Djordjevic B, Dikic N, et al. Effect of astaxanthin supplementation on
451 paraoxonase 1 activities and oxidative stress status in young soccer players. *Phytother Res.*
452 2013;27:1536-1542.

453 [18] Santos FG, Becker MK, Corrêa VS, et al. The effect of the paraoxonase 1 (PON1) T(-
454 107)C polymorphism on serum PON1 activity in women is dependent on fatty acid intake.
455 *Nutr Res.* 2016;36:9-15.

456 [19] Eryanni-Levin S, Khatib S, Levy-Rosenzvig R, Tamir S, Szuchman-Sapir A. 5,6- δ -DHTL,
457 a stable metabolite of arachidonic acid, is a potential substrate for paraoxonase 1. *Biochim*
458 *Biophys Acta.* 2015;1851:1118-1122.

459 [20] Calabresi L, Villa B, Canavesi M, et al. An ω -3 polyunsaturated fatty acid concentrate
460 increases plasma high-density lipoprotein 2 cholesterol and paraoxonase levels in patients with
461 familial combined hyperlipidemia. *Metabolism.* 2004;53:153-158.

462 [21]Shen H, Li M, Wang B, et al. Dietary antioxidants (selenium and N-acetylcysteine)
463 modulate paraoxonase 1 (PON1) in PCB 126-exposed rats. *Environ Sci Pollut Res Int.*
464 2014;21:6384-6399.

465 [22]Ghaffari T, Nouri M, Irannejad E, Rashidi MR. Effect of vitamin e and selenium
466 supplement on paraoxonase-1 activity, oxidized low density lipoprotein and antioxidant
467 defense in diabetic rats. *Bioimpacts.* 2011;1:121-128.

468 [23]Rosenblat M, Volkova N, Borochoy-Neori H, Judeinstein S, Aviram M. Anti-atherogenic
469 properties of date vs. pomegranate polyphenols: the benefits of the combination. *Food Funct.*
470 2015;6:1496-1509.

471 [24]Wang S, Moustaid-Moussa N, Chen L, et al. Novel insights of dietary polyphenols and
472 obesity. *J Nutr Biochem.* 2014;25:1-18

473 [25]Zagayko AL, Kravchenko GB, Krasilnikova OA, Ogai YO. Grape polyphenols increase
474 the activity of HDL enzymes in old and obese rats. *Oxid Med Cell Longev.*
475 2013;2013:593761.

476 [26] Crozier A, Jaganath IB, Clifford MN. Dietary phenolics: chemistry, bioavailability and
477 effects on health. *Nat Prod Rep.* 2009;26:1001-1043.

478 [27] Del Rio D, Rodriguez-Mateos A, Spencer JP, et al. Dietary (poly)phenolics in human
479 health: structures, bioavailability, and evidence of protective effects against chronic diseases.
480 *Antioxid Redox Signal.* 2013;18:1818-1892.

481 [28]Amiot MJ, Riva C, Vinet A. Effects of dietary polyphenols on metabolic syndrome
482 features in humans: a systematic review. *Obes Rev.* 2016; doi: 10.1111/obr.12409.

483 [29] Ochiai R, Sugiura Y, Otsuka K, Katsuragi Y, Hashiguchi T. Coffee bean polyphenols
484 ameliorate postprandial endothelial dysfunction in healthy male adults. *Int J Food Sci Nutr.*
485 2015;66:350-354.

486 [30]Medina-Remón A, Tresserra-Rimbau A, Pons A, et al. Effects of total dietary polyphenols
487 on plasma nitric oxide and blood pressure in a high cardiovascular risk cohort. The
488 PREDIMED randomized trial. *Nutr Metab Cardiovasc Dis.* 2015;25:60-67.

489 [31]Rostami A, Khalili M, Haghighat N, et al. High-cocoa polyphenol-rich chocolate improves
490 blood pressure in patients with diabetes and hypertension. *ARYA Atheroscler.* 2015;11:21-29.

491 [32]Li SH, Zhao P, Tian HB, Chen LH, Cui LQ. Effect of grape polyphenols on blood
492 pressure: a meta-analysis of randomized controlled trials. *PLoS One* 2015;10:e0137665.

493 [33]Yamagata K, Tagami M, Yamori Y. Dietary polyphenols regulate endothelial function and
494 prevent cardiovascular disease. *Nutrition.* 2015;31:28-37.

495 [34]Khurana S, Venkataraman K, Hollingsworth A, Piche M, Tai TC. Polyphenols: benefits to
496 the cardiovascular system in health and in aging. *Nutrients.* 2013;5:3779-3827.

497 [35]Del Bo' C, Martini D, Porrini M, Klimis-Zacas D, Riso P. Berries and oxidative stress
498 markers: an overview of human intervention studies. *Food Funct.* 2015;6:2890-2917.

499 [36]Joseph SV, Edirisinghe I, Burton-Freeman BM. Fruit polyphenols: A review of anti-
500 inflammatory effects in humans. *Crit Rev Food Sci Nutr.* 2015;23:0.

501 [37]Almeida Rezende B, Pereira AC, Cortes SF, Lemos VS. Vascular effects of flavonoids.
502 *Curr Med Chem.* 2016;23:87-102.

503 [38] Zanotti I, Dall'Asta M, Mena P, et al. Atheroprotective effects of (poly)phenols: a focus
504 on cell cholesterol metabolism. *Food Funct.* 2015;6:13-31.

505 [39] Schrader C, Ernst I, Sinnecker H, et al. Genistein as a potential inducer of the
506 anti-atherogenic enzyme paraoxonase-1: studies in cultured hepatocytes in vitro and in rat liver
507 in vivo. *J Cell Mol Med.* 2012;16:2331-2341.

508 [40] Aviram M, Dornfeld L, Rosenblat M, et al. Pomegranate juice consumption reduces
509 oxidative stress, atherogenic modifications to LDL, and platelet aggregation: studies in humans
510 and in atherosclerotic apolipoprotein E-deficient mice. *Am J Clin Nutr.* 2000;71:1062-1076.

511 [41] Rosenblat M, Volkova N, Attias J, Mahamid R, Aviram M. Consumption of
512 polyphenolic-rich beverages (mostly pomegranate and black currant juices) by healthy subjects
513 for a short term increased serum antioxidant status, and the serum's ability to attenuate
514 macrophage cholesterol accumulation. *Food Funct.* 2010;1:99-109.

515 [42] Schrader C, Schiborr C, Frank J, Rimbach G. Curcumin induces paraoxonase 1 in
516 cultured hepatocytes in vitro but not in mouse liver in vivo. *Br J Nutr.* 2011;105:167-170.

517 [43] Boesch-Saadatmandi C, Egert S, Schrader C, et al. Effect of quercetin on paraoxonase 1
518 activity-studies in cultured cells, mice and humans. *J Physiol Pharmacol.* 2010;61:99.

519 [44] Gouédard C, Barouki R, Morel Y. Dietary polyphenols increase paraoxonase 1 gene
520 expression by an aryl hydrocarbon receptor-dependent mechanism. *Mol Cell Biol.*
521 2004;24:5209-5222.

522 [45] Garige M, Gong M, Varatharajalu R, Lakshman MR. Quercetin up-regulates paraoxonase
523 1 gene expression via sterol regulatory element binding protein 2 that translocates from the
524 endoplasmic reticulum to the nucleus where it specifically interacts with sterol responsive
525 element-like sequence in paraoxonase 1 promoter in HuH7 liver cells. *Metab Clin Exp .*
526 2010;59:1372-1378.

527 [46] Khateeb J, Gantman A, Kreitenberg AJ, Aviram M, Fuhrman B. Paraoxonase 1 (PON1)
528 expression in hepatocytes is upregulated by pomegranate polyphenols: a role for PPAR- γ
529 pathway. *Atherosclerosis.* 2010;208:119-125.

530 [47] Gouédard C, Barouki R, Morel Y. Induction of the paraoxonase-1 gene expression by
531 resveratrol. *Arterioscler Thromb Vasc Biol.* 2004;24:2378-2383.

532 [48] Curtin BF, Seetharam KI, Dhoieam P, et al. Resveratrol induces catalytic bioscavenger
533 paraoxonase 1 expression and protects against chemical warfare nerve agent toxicity in human
534 cell lines. *J Cell Biochem.* 2008;103:1524-1535.

535 [49] Wagner AE, Boesch-Saadatmandi C, Breckwoldt D, et al. Ascorbic acid partly
536 antagonizes resveratrol mediated heme oxygenase-1 but not paraoxonase-1 induction in

537 cultured hepatocytes-role of the redox-regulated transcription factor Nrf2. BMC Complement
538 Altern Med. 2011;11:1.

539 [50] Guyot E, Coumoul X, Chassé JF, et al. Identification of a new stilbene-derived inducer of
540 paraoxonase 1 and ligand of the Aryl hydrocarbon Receptor. Biochem Pharmacol.
541 2012;83:627-632.

542 [51] Gupta N, Kandimalla R, Priyanka K, et al. Effect of resveratrol and nicotine on PON1
543 gene expression: in vitro Study. Indian J Clin Biochem. 2014;29: 69-73.

544 [52] Pereira RR, de Abreu IC, Guerra JF, Lage NN, Lopes JM, Silva M, de Lima WG, Silva
545 ME, Pedrosa ML. Açai (*Euterpe oleracea* Mart.) Upregulates paraoxonase 1 gene expression
546 and activity with concomitant reduction of hepatic steatosis in high-fat diet-fed rats. Oxid Med
547 Cell Longev. 2016;2016:8379105.

548 [53] Kaplan M, Hayek T, Raz A, et al. Pomegranate juice supplementation to atherosclerotic
549 mice reduces macrophage lipid peroxidation, cellular cholesterol accumulation and
550 development of atherosclerosis. J Nutr. 2001;131:2082-2089.

551 [54] Fuhrman B, Aviram M. Preservation of paraoxonase activity by wine flavonoids. Ann N
552 Y Acad Sci. 2002;957:321-324.

553 [55] Tas S, Sarandol E, Ziyank S, Aslan K, Dirican M. Effects of green tea on serum
554 paraoxonase/arylesterase activities in streptozotocin-induced diabetic rats. Nutr Res.
555 2005;25:1061-1074.

556 [56] El-Beshbishy HA, Singab ANB, Sinkkonen J, Pihlaja K. Hypolipidemic and antioxidant
557 effects of *Morus alba* L.(Egyptian mulberry) root bark fractions supplementation in
558 cholesterol-fed rats. Life Sci. 2006;78:2724-2733.

559 [57] Aksoy N, Aksoy M, Bagci C, et al. Pistachio intake increases high density lipoprotein
560 levels and inhibits low-density lipoprotein oxidation in rats. Tohoku J Exp Med. 2007;212:43-
561 48.

562 [58] Hamelet J, Demuth K, Dairou J, et al. Effects of catechin on homocysteine metabolism in
563 hyperhomocysteinemic Biochem Biophys Res Commun. 2007;355:221-227.

564 [59] Ustundag B, Bahcecioglu IH, Sahin K, et al. Protective effect of soy isoflavones and
565 activity levels of plasma paraoxonase and arylesterase in the experimental non-alcoholic
566 steatohepatitis model. Dig Dis Sci. 2007;52:2006-2014.

567 [60] Do GM, Kwon EY, Kim HJ, et al. Long-term effects of resveratrol supplementation on
568 suppression of atherogenic lesion formation and cholesterol synthesis in apo E-deficient mice.
569 Biochem Biophys Res Commun. 2008;374:55-59.

570 [61] Jang EM, Choi MS, Jung UJ, et al. Beneficial effects of curcumin on hyperlipidemia and
571 insulin resistance in high-fat-fed hamsters. Metabolism. 2008;57:1576-1583.

572 [62] Rosenblat M, Volkova N, Coleman R, Almagor Y, Aviram M. Antiatherogenicity of extra
573 virgin olive oil and its enrichment with green tea polyphenols in the atherosclerotic
574 apolipoprotein-E-deficient mice: enhanced macrophage cholesterol efflux. J Nutr Biochem.
575 2008;19:514-523.

576 [63] Gong M, Garige, M, Varatharajalu R, et al. Quercetin up-regulates paraoxonase 1 gene
577 expression with concomitant protection against LDL oxidation. Biochem Biophys Res
578 Commun. 2009;379:1001-1004.

579 [64] Noll C, Hamelet J, Ducros V, Belin N, Paul JL, Delabar JM, Janel N. Resveratrol
580 supplementation worsen the dysregulation of genes involved in hepatic lipid homeostasis
581 observed in hyperhomocysteinemic mice. Food Chem Toxic. 2009;47:230-236.

582 [65] Noll C, Hamelet J, Matulewicz E, et al. Effects of red wine polyphenolic compounds on
583 paraoxonase-1 and lectin-like oxidized low-density lipoprotein receptor-1 in
584 hyperhomocysteinemic mice. J Nutr Biochem. 2009;20:586-596.

585 [66] Boesch-Saadatmandi C, Niering J, Minihane AM, et al. Impact of apolipoprotein E
586 genotype and dietary quercetin on paraoxonase 1 status in apoE3 and apoE4 transgenic mice.
587 Atherosclerosis. 2010;211:110-113.

588 [67] K1Y1C1 A, Okudan N, Gökbel H, Belviranlı, M. The effect of grape seed extracts on serum
589 paraoxonase activities in streptozotocin-induced diabetic rats. *J Med Food*. 2010;13:725-728.

590 [68] Leckey LC, Garige M, Varatharajalu R, et al. Quercetin and ethanol attenuate the
591 progression of atherosclerotic plaques with concomitant up regulation of paraoxonase1
592 (PON1) gene expression and PON1 activity in LDLR-/- Mice. *Alcohol Clin Exp Res*.
593 2010;34:1535–1542.

594 [69] Rosenblat M, Volkova N, Aviram M. Pomegranate juice (PJ) consumption antioxidative
595 properties on mouse macrophages, but not PJ beneficial effects on macrophage cholesterol and
596 triglyceride metabolism, are mediated via PJ-induced stimulation of macrophage PON2.
597 *Atherosclerosis* 2010;212:86-92.

598 [70] Wu X, Kang J, Xie C, et al. Dietary blueberries attenuate atherosclerosis in apolipoprotein
599 E-deficient mice by upregulating antioxidant enzyme expression. *J Nutr*. 2010;140:1628-1632.

600 [71] Amengual-Cladera E, Nadal-Casellas A, Gómez-Pérez Y, et al. Phytotherapy in a rat
601 model of hyperoxaluria: the antioxidant effects of quercetin involve serum paraoxonase 1
602 activation. *Exp Biol Med*. 2011;236:1133-1138.

603 [72] Betanzos-Cabrera G, Guerrero-Solano JA, Martínez-Pérez MM, Calderón-Ramos ZG, et
604 al. Pomegranate juice increases levels of paraoxonase1 (PON1) expression and enzymatic
605 activity in streptozotocin-induced diabetic mice fed with a high-fat diet. *Food Res Int*.
606 2011;44:1381-1385.

607 [73] Kujawska M, Ignatowicz E, Ewertowska M, Markowski J, Jodynis-Liebert J. Cloudy
608 apple juice protects against chemical-induced oxidative stress in rat. *Eur J Nutr*. 2011;50:53-
609 60.

610 [74] Suh JH, Romain C, González-Barrio R, et al. Raspberry juice consumption, oxidative
611 stress and reduction of atherosclerosis risk factors in hypercholesterolemic golden Syrian
612 hamsters. *Food Funct*. 2011;2:400-405.

613 [75] Xie C, Kang J, Li Z, et al. The açai flavonoid velutin is a potent anti-inflammatory agent:
614 blockade of LPS-mediated TNF- α and IL-6 production through inhibiting NF- κ B activation
615 and MAPK pathway. *J Nutr Biochem*. 2012;23:1184-1191.

616 [76] Abdel-Salam OM, Youness ER, Mohammed NA, Abd-Elmoniem M, Omara E, Sleem
617 AA. Neuroprotective and hepatoprotective effects of micronized purified flavonoid fraction
618 (Daflon®) in lipopolysaccharide-treated rats. *Drug Discov Therap*. 2012;6:306-314.

619 [77] Bayram B, Ozcelik B, Grimm S, et al. A diet rich in olive oil phenolics reduces oxidative
620 stress in the heart of SAMP8 mice by induction of Nrf2-dependent gene expression.
621 *Rejuvenation Res*. 2012;15:71-81.

622 [78] Lee J, Cho HS, Kim DY, et al. Combined effects of exercise and soy isoflavone diet on
623 paraoxonase, nitric oxide and aortic apoptosis in ovariectomized rats. *Appetite* 2012;58:462-9.

624 [79] Romain C, Gaillet S, Carillon J, et al. Vineatrol and cardiovascular disease: beneficial
625 effects of a vine-shoot phenolic extract in a hamster atherosclerosis model. *J Agric Food*
626 *Chem*. 2012;60:11029-11036.

627 [80] Al-Rejaie SS, Aleisa AM, Sayed-Ahmed MM, et al. Protective effect of rutin on the
628 antioxidant genes expression in hypercholesterolemic male Westar rat. *BMC Complement*
629 *Altern Med*. 2013;13:136.

630 [81] Arunima S, Rajamohan T. Effect of virgin coconut oil enriched diet on the antioxidant
631 status and paraoxonase 1 activity in ameliorating the oxidative stress in rats—a comparative
632 study. *Food Funct*. 2013;4:1402-1409.

633 [82] Berbée JF, Wong MC, Wang Y, et al. Resveratrol protects against atherosclerosis, but
634 does not add to the antiatherogenic effect of atorvastatin, in apoe* 3-leiden. Cetp mice. *J Nutr*
635 *Biochem*. 2013;24:1423-1430.

636 [83] Kim B, Ku CS, Pham TX, et al. Aronia melanocarpa (chokeberry) polyphenol-rich
637 extract improves antioxidant function and reduces total plasma cholesterol in apolipoprotein E
638 knockout mice. *Nutr Res*. 2013;33:406-413.

639 [84] Mohammadshahi M, Haidari F, Saei AA, et al. Soy protein, genistein, and daidzein
640 improve serum paraoxonase activity and lipid profiles in rheumatoid arthritis in rats. *J Med*
641 *Food* 2013;16:147-154.

642 [85] Francik R, Kryczyk J, Krośniak M, et al. The neuroprotective effect of cornus MAS on
643 brain tissue of Wistar rats. *Scientific World Journal* 2014;2014: 847368.

644 [86] Hafez MM, Al-Shabanah OA, Al-Harbi NO, et al. Association between paraoxonases
645 gene expression and oxidative stress in hepatotoxicity induced by CCl₄. *Oxid Med Cell*
646 *Longev.* 2014;2014:893212.

647 [87] Jaiswal N, Rizvi SI. Onion extract (*Allium cepa* L.), quercetin and catechin up-regulate
648 paraoxonase 1 activity with concomitant protection against low-density lipoprotein oxidation
649 in male Wistar rats subjected to oxidative stress. *J Sci Food Agric.* 2014;94:2752-2757.

650 [88] Farrell N, Norris G, Lee SG, Chun OK, Blesso CN. Anthocyanin-rich black elderberry
651 extract improves markers of HDL function and reduces aortic cholesterol in hyperlipidemic
652 mice. *Food Funct.* 2015;6:1278-1287.

653 [89] Huang TW, Chang CL, Kao ES, Lin JH. Effect of *Hibiscus sabdariffa* extract on high fat
654 diet-induced obesity and liver damage in hamsters. *Food Nutr Res.* 2015;59:29018.

655 [90] Rosenblat M, Volkova N, Borochoy-Neori H, Judeinstein S, Aviram M. Anti-atherogenic
656 properties of date vs. pomegranate polyphenols: the benefits of the combination. *Food Funct.*
657 2015;6:1496-1509.

658 [91] Freese R, Alfthan G, Jauhiainen M, et al. High intakes of vegetables, berries, and apples
659 combined with a high intake of linoleic or oleic acid only slightly affect markers of lipid
660 peroxidation and lipoprotein metabolism in healthy subjects. *Am J Clin Nutr.* 2002;76:950-
661 960.

662 [92] Fuhrman B, Volkova N, Kaplan M, et al. Antiatherosclerotic effects of licorice extract
663 supplementation on hypercholesterolemic patients: increased resistance of LDL to atherogenic

664 modifications, reduced plasma lipid levels, and decreased systolic blood pressure. *Nutrition*.
665 2002;18:268-273.

666 [93] Aviram M, Rosenblat M, Gaitini D, et al. Pomegranate juice consumption for 3 years by
667 patients with carotid artery stenosis reduces common carotid intima-media thickness, blood
668 pressure and LDL oxidation. *Clin Nutr*. 2004;23:423-433.

669 [94] Cherki M, Derouiche A, Drissi A, et al. Consumption of argan oil may have an
670 antiatherogenic effect by improving paraoxonase activities and antioxidant status: Intervention
671 study in healthy men. *Nutr Metab Cardiovasc Dis*. 2005;15:352-360.

672 [95] Rosenblat M, Hayek T, Aviram M. Anti-oxidative effects of pomegranate juice (PJ)
673 consumption by diabetic patients on serum and on macrophages. *Atherosclerosis*.
674 2006;187:363-371.

675 [96] Suomela JP, Ahotupa M, Yang B, Vasankari T, Kallio H. Absorption of flavonols derived
676 from sea buckthorn (*Hippophaë rhamnoides* L.) and their effect on emerging risk factors for
677 cardiovascular disease in humans. *J Agric Food Chem*. 2006;54:7364-7369.

678 [97] Dalgård C, Christiansen L, Jonung T, et al. No influence of increased intake of orange and
679 blackcurrant juices and dietary amounts of vitamin E on paraoxonase-1 activity in patients
680 with peripheral arterial disease. *Eur J Nutr*. 2007;46:354-363.

681 [98] Hsu SP, Wu MS, Yang CC, et al. Chronic green tea extract supplementation reduces
682 hemodialysis-enhanced production of hydrogen peroxide and hypochlorous acid,
683 atherosclerotic factors, and proinflammatory cytokines. *Am J Clin Nutr*. 2007;86:1539-1547.

684 [99] Rock W, Rosenblat M, Miller-Lotan R, et al. Consumption of wonderful variety
685 pomegranate juice and extract by diabetic patients increases paraoxonase 1 association with
686 high-density lipoprotein and stimulates its catalytic activities. *J Agric Food Chem*.
687 2008;56:8704-8713.

688 [100] Strunz CC, Oliveira TV, Vinagre JC, Lima A, et al. Brazil nut ingestion increased
689 plasma selenium but had minimal effects on lipids, apolipoproteins, and high-density
690 lipoprotein function in human subjects. *Nutr Res.* 2008;28:151-155.

691 [101] Rock W, Rosenblat M, Borochoy-Neori H, et al. Effects of date (*Phoenix dactylifera* L.,
692 Medjool or Hallawi Variety) consumption by healthy subjects on serum glucose and lipid
693 levels and on serum oxidative status: a pilot study. *J Agric Food Chem.* 2009;57:8010-8017.

694 [102] Cesar TB, Aptekmann NP, Araujo MP, Vinagre CC, Maranhão RC. Orange juice
695 decreases low-density lipoprotein cholesterol in hypercholesterolemic subjects and improves
696 lipid transfer to high-density lipoprotein in normal and hypercholesterolemic subjects. *Nutr*
697 *Res* 2010;30: 689-694.

698 [103] Fuhrman B, Volkova N, Aviram M. Pomegranate juice polyphenols increase
699 recombinant paraoxonase-1 binding to high-density lipoprotein: studies in vitro and in diabetic
700 patients. *Nutrition.* 2010;26:359-366.

701 [104] Huebbe P, Giller K, de Pascual-Teresa S, et al. Effects of blackcurrant-based juice on
702 atherosclerosis-related biomarkers in cultured macrophages and in human subjects after
703 consumption of a high-energy meal. *Br J Nutr.* 2012;108:234-244.

704 [105] Parsaeyan N, Mozaffari-Khosravi H, Mozayan MR. Effect of pomegranate juice on
705 paraoxonase enzyme activity in patients with type 2 diabetes. *J Diabetes Metab Disord.*
706 2012;11:11.

707 [106] Shidfar F, Heydari I, Hajimiresmaiel SJ, et al. The effects of cranberry juice on serum
708 glucose, apoB, apoA-I, Lp (a), and Paraoxonase-1 activity in type 2 diabetic male patients. *J*
709 *Res Med Sci.* 2012;17:355.

710 [107] Loued S, Berrougui H, Componova P, et al. Extra-virgin olive oil consumption reduces
711 the age-related decrease in HDL and paraoxonase 1 anti-inflammatory activities. *Br J Nutr.*
712 2013;110:1272-1284.

713 [108] Kardum N, Konić-Ristić A, Savikin K, et al. Effects of polyphenol-rich chokeberry juice
714 on antioxidant/pro-oxidant status in healthy subjects. *J Med Food*. 2014;17:869-874.

715 [109] Zhu Y, Huang X, Zhang Y, et al., Anthocyanin supplementation improves HDL-
716 associated paraoxonase 1 activity and enhances cholesterol efflux capacity in subjects with
717 hypercholesterolemia. *J Clinical Endocrinol Metab*. 2013;99:561-569.

718 [110] Deáková Z, Országhová Z, Andrezálová L, et al., Influence of oak wood polyphenols on
719 cysteine, homocysteine and glutathione total levels and PON1 activities in human adult
720 volunteers—a pilot study. *Gen Physiol Biophys*. 2015;34:73-80.

721 [111] Farràs M, Castañer O, Martín-Peláez S, et al., Complementary phenol-enriched olive oil
722 improves HDL characteristics in hypercholesterolemic subjects. A randomized, double-blind,
723 crossover, controlled trial. The VOHF study. *Mol Nutr Food Res*. 2015;59:1758-1770.

724 [112] Tracy CR, Henning JR, Newton MR, et al., Oxidative stress and nephrolithiasis: a
725 comparative pilot study evaluating the effect of pomegranate extract on stone risk factors and
726 elevated oxidative stress levels of recurrent stone formers and controls. *Urolithiasis*.
727 2014;42:401-408.

728 [113] Wu PT, Fitschen PJ, Kistler BM, et al., Effects of pomegranate extract supplementation
729 on cardiovascular risk factors and physical function in hemodialysis patients. *J Med Food*.
730 2015;18:941-949.

731 [114] Ciolino HP, Daschner PJ, Yeh GC. Dietary flavonols quercetin and kaempferol are
732 ligands of the aryl hydrocarbon receptor that affect CYP1A1 transcription differentially.
733 *Biochem J*. 1999;340(Pt 3):715–722.

734 [115] Costa LG, Giordano G, Furlong CE. Pharmacological and dietary modulators of
735 paraoxonase 1 (PON1) activity and expression: the hunt goes on. *Biochem Pharmacol*.
736 2011;81:337-344.

737 [116] Osaki F, Ikeda Y, Suehiro T, et al., Roles of Sp1 and protein kinase C in regulation of
738 human serum paraoxonase 1 (PON1) gene transcription in HepG2 cells. *Atherosclerosis*.
739 2004;176:279-287.

740 [117] Arai K, Suehiro T, Ota K, et al. Pitavastatin induces PON1 expression through p44/42
741 mitogen-activated protein kinase signaling cascade in Huh7 cells. *Atherosclerosis*.
742 2009;202:439-445.

743 [118] Singh R, Ahmed S, Malemud CJ, Goldberg VM, Haqqi TM. Epigallocatechin-3-gallate
744 selectively inhibits interleukin-1beta-induced activation of mitogen activated protein kinase
745 subgroup c-Jun N-terminal kinase in human osteoarthritis chondrocytes. *J Orthop Res*.
746 2003;21:102-109.

747 [119] Vari R, Scazzocchio B, Santangelo C, et al. Protocatechuic acid prevents oxLDL-
748 induced apoptosis by activating JNK/Nrf2 survival signals in macrophages. *Oxid Med Cell*
749 *Longev*. 2015;2015:351827.

750 [120] Précourt LP, Amre D, Denis MC, et al. The three-gene paraoxonase family: physiologic
751 roles, actions and regulation. *Atherosclerosis*. 2011; 214:20-36.

752 [121] Chiba T, Inoko H, Kimura M, Sato T. Role of nuclear I κ Bs in inflammation regulation.
753 *Biomol Concepts*. 2013;4:187-196.

754 [122] Lee SG, Kim B, Yang Y, et al. Berry anthocyanins suppress the expression and secretion
755 of proinflammatory mediators in macrophages by inhibiting nuclear translocation of NF- κ B
756 independent of NRF2-mediated mechanism. *J Nutr Biochem*. 2014;25:404-411.

757 [123] Mena P, Domínguez-Perles R, Gironés-Vilaplana A, et al. Flavan-3-ols, anthocyanins,
758 and inflammation. *IUBMB Life*. 2014;66:745-758.

759 [124] Atrahimovich D, Vaya J, Khatib S. The effects and mechanism of flavonoid-rePON1
760 interactions. Structure-activity relationship study. *Bioorg Med Chem*. 2013;21:3348-3355.

761 [125] Atrahimovich D, Vaya J, Tavori H, Khatib S. Glabridin protects paraoxonase 1 from
762 linoleic acid hydroperoxide inhibition via specific interaction: a fluorescence-quenching study.
763 J Agric Food Chem. 2012;60:3679-3685.

764 [126] Center for Drug Evaluation and Research, Center for Biologics Evaluation and Research
765 (2002) Estimating the safe starting dose in clinical trials for therapeutics in adult healthy
766 volunteers, U.S. Food and Drug Administration Rockville, Maryland, USA.

767

768

769

FIGURE CAPTION 1

Fig. 1 Flow chart highlighting the study selection

FIGURE CAPTION 2

Fig. 2 Polyphenols in the modulation of PON1 activity and expression: the mechanisms of action